- Home
- OTIS vs ARGX Comparison
OTIS vs ARGX Comparison
Compare OTIS & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTIS
- ARGX
- Stock Information
- Founded
- OTIS 1853
- ARGX 2008
- Country
- OTIS United States
- ARGX Netherlands
- Employees
- OTIS N/A
- ARGX N/A
- Industry
- OTIS Consumer Electronics/Appliances
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OTIS Technology
- ARGX Health Care
- Exchange
- OTIS Nasdaq
- ARGX Nasdaq
- Market Cap
- OTIS 37.7B
- ARGX 40.4B
- IPO Year
- OTIS N/A
- ARGX 2017
- Fundamental
- Price
- OTIS $98.52
- ARGX $596.20
- Analyst Decision
- OTIS Hold
- ARGX Strong Buy
- Analyst Count
- OTIS 7
- ARGX 20
- Target Price
- OTIS $101.00
- ARGX $699.56
- AVG Volume (30 Days)
- OTIS 2.9M
- ARGX 465.0K
- Earning Date
- OTIS 04-23-2025
- ARGX 05-08-2025
- Dividend Yield
- OTIS 1.58%
- ARGX N/A
- EPS Growth
- OTIS 20.06
- ARGX N/A
- EPS
- OTIS 4.07
- ARGX 12.78
- Revenue
- OTIS $14,261,000,000.00
- ARGX $2,248,205,000.00
- Revenue This Year
- OTIS $3.56
- ARGX $57.86
- Revenue Next Year
- OTIS $4.12
- ARGX $31.90
- P/E Ratio
- OTIS $24.21
- ARGX $43.64
- Revenue Growth
- OTIS 0.37
- ARGX 77.22
- 52 Week Low
- OTIS $89.70
- ARGX $352.77
- 52 Week High
- OTIS $106.83
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- OTIS 49.62
- ARGX 51.80
- Support Level
- OTIS $96.41
- ARGX $583.00
- Resistance Level
- OTIS $99.72
- ARGX $610.06
- Average True Range (ATR)
- OTIS 3.43
- ARGX 24.42
- MACD
- OTIS -0.09
- ARGX 4.74
- Stochastic Oscillator
- OTIS 54.28
- ARGX 84.66
About OTIS Otis Worldwide Corporation
Otis Worldwide Corp is the largest global elevator and escalator supplier by revenue with around 18% global market share. In 1854 Otis' founder and namesake Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed. The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15- to 20-year useful life of an elevator. As the largest global OEM, Otis has amassed an installed base under service that exceeds 2 million elevators. Its business model is similar to that of its closest competitors Kone, Schindler, and TK Elevator.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.